Guardant Health continues to build real-world validation for its Shield multi-cancer detection (MCD) test, using intended-use data to refine performance ahead of potential regulatory submission. The blood-based assay functions as an opt-in expansion to Guardant’s already FDA-approved Shield colorectal screening, adding signal detection across nine additional cancers. The company highlighted a plan to collect data in a “real setting” while keeping the MCD assay algorithm locked for the moment—framing the dataset as a pre-study that can guide modifications without waiting for a full prospective validation trial. The reporting reflects how multi-cancer early detection developers are increasingly prioritizing real-world evidence collection to support future label and regulatory pathways.